Found 16 matching trials
Donor CHIP and Allogeneic HSCT Outcome
N/ACurrent data on the impact of donor CHIP on long-term recipient outcome rem...
Location
The University of Hong Kong
Allo HSCT Using RIC for Hematological Diseases
PHASE2This is a phase II trial using a non-myeloablative cyclophosphamide/ fludar...
Location
Masonic Cancer Center at University of Minnesota
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
PHASE2This randomized phase II trial studies how well treosulfan and fludarabine ...
Location
Fred Hutch/University of Washington Cancer Consortium
Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors
NAStem cells collected from sibling donors for allogenic transplants contain ...
Status
Active Not Recruiting
Location
University of Alabama Hospital
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
PHASE3The study is designed as a Phase III, multi-center trial of tandem autologo...
Location
University of Alabama at Birmingham
Tandem Auto-Allo Transplant for Lymphoma
PHASE2Relapse remains a principle cause of treatment failure for patients with ag...
Location
Massachusetts General Hospital
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
PHASE1This phase I/II trial studies the side effects and the best dose of inotuzu...
Location
M D Anderson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
PHASE1This phase I trial studies the side effects and maximum tolerated dose of y...
Location
Fred Hutch/University of Washington Cancer Consortium
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
PHASE2The purpose of this study is to determine if double autologous then allogen...
Location
Stanford University School of Medicine
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
PHASE2To evaluate the toxicity and tolerability of this tandem autologous/allogen...
Location
Stanford University School of Medicine